sotorasib

Start here

Report excerpt

A systematic review and meta-analysis found that prior ICI exposure was associated with higher risk of severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer (13.2% vs 4.4%, RR 3.00, 95% CI 1.76-5.10), but matched analyses detected no difference at 6-week (RR 1.11) and 12-week (RR 1.08) intervals.

Excerpted from medrxiv.org

Coverage timeline

Follow the coverage to see the different angles.

Oct 25

20:57
mp.weixin.qq.com

Oct 15

20:00
clinicaltrials.gov
Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia

Oct 7

08:00
medrxiv.org
Prior immune checkpoint inhibitor exposure, treatment interval, and severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer: a systematic review and meta-analysis
A systematic review and meta-analysis found that prior ICI exposure was associated with higher risk of severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer (13.2% vs 4.4%, RR 3.00, 95% CI 1.76-5.10), but matched analyses detected no difference at 6-week (RR 1.11) and 12-week (RR 1.08) intervals.

Apr 22

Apr 19

21:30
x.com
#AACR26

Heat trend for this story

Heat now 6·Peak in the comparable set 10 (Oct 25 21:00)·Change over 24h in the comparable set –·Participants now 1

Participants counted1

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.